Tin tức & Cập nhật
Lọc theo Chuyên ngành:

Bevacizumab + EGFR-TKI improves OS in EGFR-mutated NSCLC with leptomeningeal metastases
20 Mar 2024
bởiSarah Cheung
Adding bevacizumab to an EGFR tyrosine kinase inhibitor (TKI) improves overall survival (OS) in adult patients with EGFR-mutated non-small-cell lung cancer (NSCLC) and leptomeningeal metastases (LMs), according to a single-centre, retrospective, real-world study in China. OS was, however, similar between patients on chemotherapy plus EGFR-TKI and those on EGFR-TKI monotherapy.